Marc Sirvent

Marc Sirvent

Auto-generated profile, based on publicly available information

Marc Sirvent

Hospital General de Granollers, Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
SVSaray Varona
Saray Varona
LPLidia Puertas
Lidia Puertas
Maria GalanMaria Galan
Maria Galan
MOMar Orriols
Mar Orriols
Laia Cañes EsteveLaia Cañes Esteve
Laia Cañes Esteve
Cristina RodriguezCristina Rodriguez
Cristina Rodriguez
Abdominal aortic aneurysm (AAA) is a common life-threatening condition characterized by exacerbated inflammation and the generation of reactive oxygen species. Pharmacological treatments to slow AAA progression or to prevent its rupture remain a challenge. Targeting phosphodiesterase 4 (PDE4) has been verified as an effective therapeutic strategy for an array of inflammatory conditions; however, no studies have assessed yet PDE4 in AAA. Here, we used angiotensin II (AngII)-infused apolipoprotein E deficient mice to study the involvement of the PDE4 subfamily in aneurysmal disease. PDE4B but not PDE4D was upregulated in inflammatory cells from both experimental and human AAA. The administration of the PDE4 selective inhibitor rolipram (3 mg/kg/day) to AngII-challenged mice (1000 ng/kg bodyweight/min) protected against AAA formation, limiting the progressive increase in the aortic diameter without affecting the blood pressure. The drug strongly attenuated the rise in vascular oxidative stress (superoxide anion) induced by AngII, and decreased the expression of inflammatory markers, as well as the recruitment of macrophages (MAC3+), lymphocytes (CD3+), and neutrophils (ELANE+) into the vessel wall. Rolipram also normalized the vascular MMP2 expression and MMP activity, preserving the elastin integrity and improving the vascular remodelling. These results point to PDE4B as a new therapeutic target for AAA.

3 June 2026 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Open access
MSMarc Sirvent
Marc Sirvent
CRClaudia Riera
Claudia Riera
MGMiquel Gil
Miquel Gil
XMXavier Martí-Mestre
Xavier Martí-Mestre
VAVicenç Artigas
Vicenç Artigas
Sergi Bellmunt MontoyaSergi Bellmunt Montoya
Sergi Bellmunt Montoya
Plain balloon angioplasty (PBA) remains the standard technique for vessel preparation in peripheral artery disease. This prospective, single centre, single blind, parallel group, superiority randomised trial enrolled chronic limb threatening ischaemia (CLTI) patients with femoropopliteal (FP) lesions. It evaluated whether AngioSculpt scoring balloon (SB) use, compared with PBA, before Luminor drug coated balloon (DCB) angioplasty in FP lesions and CLTI reduces the need for bailout stenting and improves patency without increasing procedural costs. Patients with FP disease and Rutherford category 4 or 5 were randomised to PBA (control) or SB as vessel preparation. Sample size was calculated based on expected bailout stenting rates from previous studies, requiring 39 patients per arm. The primary endpoint was bailout stenting, defined as stent implantation during the index procedure for residual stenosis > 30% or type C dissection (Kobayashi classification). Secondary endpoints included primary patency, defined as duplex ultrasound peak systolic velocity ratio < 2.5 without clinically driven target lesion revascularisation, and procedural cost, defined as the total cost of all balloons and stents used during the index procedure. Eighty-three subjects were enrolled between September 2020 and November 2022 (43 SB, 40 PBA). Mean follow up was 517 ± 272 days. Mean lesion length was 235 ± 134 mm in the SB group and 219 ± 130 mm in the control. Bailout stenting was required in 33% of PBA vs. 5% of SB (p = .003). Overall primary patency was higher in the SB group (91% vs. 70%; p = .035). Procedural costs were €108 lower per patient in the SB cohort (p = .003). In this study, the use of a SB for vessel preparation prior to DCB angioplasty in CLTI patients with FP lesions significantly reduced the need for bailout stenting and was associated with improved primary patency and lower procedural costs compared with PBA. (ClinicalTrials registration ID: NCT07136883).

29 April 2024 in Revista de la Facultad de Medicina Humana
Verified
Journal Article
Open access
PDF file
EBEspaña Universidad Autónoma de Barcelona. Barcelona
España Universidad Autónoma de Barcelona. Barcelona
JJJordi Viadé Julià
Jordi Viadé Julià
JLJohn C. Longa López
John C. Longa López
MPMaria Nicolás Piera
Maria Nicolás Piera
MLMiquel Sabrià Leal
Miquel Sabrià Leal
EBEspaña. Hospital Universitario Germans Trias i Pujol. Badalona
España. Hospital Universitario Germans Trias i Pujol. Badalona
Diabetic foot is one of the most prevalent and severe complications that can develop in patients with diabetes mellitus, presenting numerous clinical challenges due to the complexity of the lesions and the multiple associated comorbidities. Effective resolution of this condition requires coordinated participation from a multidisciplinary team of specialists, including endocrinologists, surgeons, orthopedists, and specialized nurses. The objective of this paper is to present the "System for the Evaluation and Treatment of Diabetic Foot" as an integral and user-friendly tool that facilitates the management of diabetic foot in various clinical settings, including primary care, hospitals, and emergency services. This system standardizes evaluation and treatment, enhances communication among professionals, and has demonstrated, over more than 20 years, a significant reduction in the number of amputations and an improvement in clinical outcomes for patients.

6 January 2026 in medRxiv
Verified
Preprint
Open access
PDF file
BSBenedict Stanberry
Benedict Stanberry
KDKoen Deloose
Koen Deloose
YGYann Gouëffic
Yann Gouëffic
GGGilles Goyault
Gilles Goyault
GIGiacomo Isernia
Giacomo Isernia
MSMarc Sirvent
Marc Sirvent
Objective: Rotational percutaneous mechanical thrombectomy with adjunctive angioplasty, stenting or limited thrombolysis (rPMT+) has become commonplace in the treatment of acute and subacute limb ischaemia. This systematic review and proportional meta-analysis synthesises the available evidence on its safety and efficacy. Data Sources: MEDLINE, Embase and the Cochrane Library. ≥ Review Methods: We searched for studies (≥10 patients) published since 1 January 2012 (PROSPERO protocol CRD420251015846). Risk of bias was assessed using RoBANS 2. Proportional meta-analysis maximised representative sample sizes by incorporating both single-arm and comparative studies. GRADE evidence profiles were developed for each outcome of interest. Results: Twenty-four studies – seven comparative and 17 single arm – containing 2,954 procedures (2,697 rPMT+, 257 controls) met eligibility criteria. There were no randomised controlled trials. The pooled technical success (TS) rate for rPMT+ was 98% (95% CI: 97-100%, p <0.001). Amputation-free survival (AFS) was 96% (95% CI: 93-98%, p <0.001). Twelve-month primary patency (PP) was 68% (95% CI: 55-79%, p <0.001). The pooled rate of freedom from clinically-driven target lesion revascularisation (fCDTLR) was 85% (95% CI: 80-90%, p <0.001). No significant differences existed between acute, subacute and mixed subgroups. Procedure-related mortality was 0.5% (11 deaths in 2,086 procedures from 17 studies) with most deaths occurring after adjunctive catheter-directed thrombolysis. Major adverse events occurred in 4% of procedures (95% CI: 1-8%, p <0.001) and distal embolization in 8% (95% CI: 5-11%, p <0.001). rPMT+ reduced length of stay by 1.7 days versus alternatives (95% CI: 3.3-0.1 days, p <0.05). All outcomes demonstrated heterogeneity. GRADE assessment rated evidence certainty as low to very low. Conclusion: rPMT+ delivers consistently high TS and AFS rates, promising 12-month fCDTLR, acceptable PP, low procedural risk and shorter hospital stays than comparators. The consistency of favourable outcomes supports its use as a safe and effective treatment in appropriately selected ALI and SLI patients. WHAT THIS PAPER ADDS: This systematic review and proportional meta-analysis synthesises 24 single-arm and comparative non randomised studies encompassing nearly 3,000 procedures to provide a comprehensive assessment of the safety and efficacy of rotational percutaneous mechanical thrombectomy in patients with acute and subacute lower limb ischaemia. It demonstrates that, when used for initial revascularisation prior to adjunctive angioplasty, stenting or limited thrombolysis, this endovascular approach delivers consistently high rates of technical success and amputation-free survival with notably high rates of freedom from clinically-driven target lesion revascularisation, acceptable primary patency, low procedural risk and significantly shorter hospital stays.

11 August 2026 in Journal of Endovascular Therapy
Verified
Journal Article
Open access
BSBenedict Stanberry
Benedict Stanberry
KDKoen Deloose
Koen Deloose
YGYann Gouëffic
Yann Gouëffic
GGGilles Goyault
Gilles Goyault
GIGiacomo Isernia
Giacomo Isernia
MSMarc Sirvent
Marc Sirvent
Objective: Rotational percutaneous mechanical thrombectomy with adjunctive angioplasty, stenting or limited thrombolysis (rPMT+) has become commonplace in the treatment of acute and subacute limb ischaemia (SLI). This systematic review and proportional meta-analysis synthesises the available evidence on its safety and efficacy. Data Sources: MEDLINE, Embase and the Cochrane Library. Review Methods: We searched for studies (≥10 patients) published since January 1, 2012 (PROSPERO protocol CRD420251015846). Risk of bias was assessed using RoBANS 2. Proportional meta-analysis maximised representative sample sizes by incorporating both single-arm and comparative studies. The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) evidence profiles were developed for each outcome of interest. Results: Twenty-four studies – 7 comparative and 17 single arm – containing 2954 procedures (2697 rPMT+, 257 controls) met eligibility criteria. There were no randomised controlled trials. The pooled technical success (TS) rate for rPMT+ was 98% (95% confidence interval [CI]: 97%–100%, p < .001). Amputation-free survival (AFS) was 96% (95% CI: 93%–98%, p < .001). Twelve-month primary patency (PP) was 68% (95% CI: 55%–79%, p < .001). The pooled rate of freedom from clinically-driven target lesion revascularisation was 85% (95% CI: 80%–90%, p < .001). No significant differences existed between acute, subacute and mixed subgroups. Procedure-related mortality was 0.5% (11 deaths in 2086 procedures from 17 studies) with most deaths occurring after adjunctive catheter-directed thrombolysis. Major adverse events occurred in 4% of procedures (95% CI: 1%–8%, p < .001) and distal embolisation in 8% (95% CI: 5%–11%, p < .001). rPMT+ reduced length of stay by 1.7 days versus alternatives (95% CI: 3.3%–0.1 days, p < .05). All outcomes demonstrated heterogeneity; GRADE assessment rated evidence certainty as low to very low. Conclusion: The evidence available from 24 real-world observational studies of 2954 procedures supports the use of rPMT+ in acute limb ischaemia and SLI – delivering an overall pooled TS rate of 98% and AFS rate of 96% with no significant differences between acute, subacute and mixed subgroups. rPMT+ is associated with shorter hospital stays than either surgery or thrombolysis. Clinical Impact: This systematic review and proportional meta-analysis synthesises 24 single-arm and comparative non-randomised studies encompassing nearly 3000 procedures to provide a comprehensive assessment of the safety and efficacy of rotational percutaneous mechanical thrombectomy in patients with acute and subacute lower limb ischaemia. It demonstrates that, when used for initial revascularisation prior to adjunctive angioplasty, stenting or limited thrombolysis, this endovascular approach delivers clinically valuable rates of technical success and amputation-free survival with notably high rates of freedom from clinically-driven target lesion revascularisation, acceptable primary patency, low procedural risk and significantly shorter hospital stays.